Key takeaways:

• Peptides are promised as a solution for aging, muscle loss, metabolic dysfunction and wrinkles.
• Evidence on the safety and efficacy of many peptides remains limited and physician caution is warranted.

Few molecules in medicine generate as much excitement — and as much noise — as peptides.

Walk into any medical spa, open any luxury skin care brand’s website or scroll through a longevity-focused biohacking forum and you will find peptides promised as the solution to wrinkles, muscle loss, metabolic dysfunction and aging itself. What you will find far less frequently is a rigorous accounting of what the evidence actually supports.

As a dermatologist-scientist, I am constantly asked about peptides — by patients shopping for serums, by colleagues curious about injectables and increasingly by patients who have been prescribed peptide therapies by concierge medicine physicians and want to know whether they should apply them to their skin as well.

The answer, as with most things in medicine, depends entirely on which peptide, which route of administration and which outcome you are asking about.

Collagen-building peptides

Collagen-building peptides have the longest track record in dermatology and the strongest topical evidence base. They work by one of three broad mechanisms: acting as direct substrates or fragments that signal fibroblasts to upregulate collagen synthesis; chelating copper to activate lysyl oxidase and crosslink collagen fibers; or functioning as matrikines — fragments of extracellular matrix proteins that feed back on fibroblasts to signal repair.

Palmitoyl pentapeptide-4 (Matrixyl)

Perhaps the most widely studied cosmeceutical peptide is palmitoyl pentapeptide-4. It is a lipid-conjugated lysine-threonine-threonine-lysine-serine sequence that mimics a fragment of type I procollagen and stimulates fibroblast production of collagen I, III and fibronectin.

Strong topical evidence includes a double-blind, randomized, split-face study published in the International Journal of Cosmetic Science that demonstrated significant reductions in wrinkle depth with twice-daily application at 3 and 4 ppm concentrations over 8 weeks compared with vehicle.

Additional peer-reviewed work has confirmed upregulation of collagen synthesis markers in ex vivo human skin models.

Clinical note: Concentration matters. Most over-the-counter products list Matrixyl without disclosing concentration. Studies showing efficacy used 3 to 4 ppm. Advise patients to look for products listing it in the top half of the ingredient list.

Copper peptide (GHK-Cu)

Glycyl-L-histidyl-L-lysine complexed with copper(II) is one of the oldest and most studied cosmeceutical peptides, with research extending back to the work of Loren Pickart, PhD, in the 1970s. GHK-Cu occurs naturally in plasma, saliva and urine and declines with age. It promotes wound healing, stimulates collagen and glycosaminoglycan synthesis and activates superoxide dismutase, lending it antioxidant properties.

Strong topical evidence includes multiple studies that support improved skin laxity, reduced fine lines and enhanced wound healing with topical GHK-Cu. A randomized, double-blind trial found GHK-Cu cream significantly improved skin density and thickness on the face versus placebo after 12 weeks of use.

GHK-Cu has attracted longevity research interest for systemic use; however, systemic administration in humans for cosmetic or anti-aging indications lacks robust trial evidence. Copper homeostasis is tightly regulated, and exogenous systemic copper delivery carries real risks. Excess copper is hepatotoxic, can catalyze free-radical oxidative damage via Fenton-type reactions and has been implicated in neurodegeneration. There are no established safe dosing ranges for cosmetic systemic GHK-Cu in healthy adults and no long-term human safety trials.

Palmitoyl tripeptide-1 and tripeptide-38 (Matrixyl 3000)

Often paired commercially as “Matrixyl 3000,” palmitoyl tripeptide-1 and tripeptide-38 combination delivers palmitoyl tripeptide-1, a collagen-I-mimicking signal, alongside palmitoyl tripeptide-38, which stimulates collagen I, III, IV, fibronectin and hyaluronic acid. In vitro data and early clinical studies suggest synergistic activity. Split-face studies have shown improvement in wrinkle volume and depth at 8 weeks. Evidence is less robust than for the original Matrixyl but growing.

Dipalmitoyl hydroxyproline (Sepilift DPHP)

Dipalmitoyl hydroxyproline (DPHP), marketed as Sepilift by Seppic, is a lipophilic derivative of hydroxyproline — the amino acid that constitutes approximately 14% of the collagen triple helix and is critical to its structural stability. By conjugating hydroxyproline with two palmitoyl chains, DPHP achieves excellent stratum corneum penetration, offering a meaningful advantage over larger, more hydrophilic peptides. Once absorbed, it acts as a direct substrate replenishment signal, supporting fibroblast collagen synthesis and, critically, upregulating integrin expression at the dermal-epidermal junction, which improves the structural anchoring of the epidermis to the dermis.

Topical evidence for DPHP includes industry-sponsored clinical trials demonstrating improvements in skin firmness, elasticity and the appearance of fine lines with regular application. Its mechanism differs from the matrikine-type signaling of Matrixyl peptides. Rather than mimicking a collagen fragment to trigger a repair response, it delivers a structural building block directly. This makes it complementary to rather than duplicative of Matrixyl-type peptides in formulation.

One 28-day clinical study reported measurable improvement in skin lifting and firmness parameters assessed by cutometry. Independent peer-reviewed data for DPHP are more limited than the data for GHK-Cu or palmitoyl pentapeptide-4; however, the mechanistic rationale is well-grounded, and penetration data are favorable given its lipophilic architecture.

Formulation note: The dipalmitoyl conjugation gives DPHP an oily texture that lends itself particularly well to anhydrous formulations, balms and oil-in-water emulsions. It is frequently combined with other collagen-building peptides and hyaluronic acid in premium anti-aging serums. Its lipophilicity also makes it more stable than many hydrophilic peptides, which are susceptible to hydrolysis in aqueous formulations.

Clinical note: Sepilift DPHP is a useful addition to a collagen-support regimen precisely because its mechanism — substrate delivery and integrin upregulation — is distinct from SNARE-mimic and matrikine approaches. Formulations combining DPHP with palmitoyl pentapeptide-4 or GHK-Cu are addressing collagen biology through complementary, nonredundant pathways.

Neuromodulatory (“Botox-like”) peptides

Neuromodulatory peptides have attracted the most consumer interest and perhaps the most overstatement. These peptides aim to reduce dynamic line formation by interfering with the SNARE complex responsible for acetylcholine release at the neuromuscular junction, mimicking in a far more modest way the mechanism of botulinum toxin. Although these peptides have a reasonable topical safety profile when used as intended, systemic administration — whether injectable, oral or via other routes — raises serious and largely unstudied safety concerns.

Acetyl hexapeptide-3 (Argireline)

The most commercially prominent neuromodulatory peptide, Argireline, is a hexapeptide analog of the N-terminal of SNAP-25, one of the SNARE complex proteins. By competing with SNAP-25 for binding sites, it theoretically reduces vesicular acetylcholine release and thus attenuates muscle contraction.

Topical evidence includes studies that have demonstrated modest but statistically significant reductions in periorbital wrinkle depth in controlled trials at concentrations of 10%. One well-designed randomized trial showed a 30% reduction in wrinkle depth vs. vehicle after 4 weeks. Crucially, penetration is the limiting factor. The peptide must reach the dermal-epidermal junction and beyond to have meaningful neuromuscular effects.

There are no head-to-head randomized controlled trials comparing Argireline with botulinum toxin A for any indication. Mechanistically, the effects are analogous, but the magnitude is incomparable. Argireline is best framed to patients as a modest adjunct or maintenance tool, not a substitute for neurotoxin.

Clinical note: Patients asking about Argireline often conflate it with injectable neurotoxin. Framing is important. It relaxes surface muscle tone modestly; it does not freeze a muscle or provide the lifting effect of a well-placed botulinum toxin A injection.

Leuphasyl

Leuphasyl is a pentapeptide that targets the enkephalin pathway, inhibiting the catecholamine cascade that leads to muscle contraction. It is often combined with Argireline, as the two act on different steps of the neuromuscular signaling pathway for purported synergistic effect. Peer-reviewed randomized controlled trial data independent of industry sponsorship are limited.

SYN-AKE (dipeptide diaminobutyroyl benzylamide diacetate)

SYN-AKE is a synthetic tripeptide mimicking waglerin-1, the active component of Temple Viper venom, which acts as an antagonist at the muscular nicotinic acetylcholine receptor. Unlike Argireline, which targets the presynaptic SNARE complex, SYN-AKE acts postsynaptically. Manufacturer studies report significant reduction in forehead line depth; independent peer-reviewed trials are limited.

Clinical note: Most peptides are hydrophilic, relatively large molecules (500-3,000 Da). The stratum corneum preferentially allows passage of lipophilic molecules under 500 Da. Lipid conjugation (palmitoylation), encapsulation in liposomes or nanoparticles, and disruption of the barrier with acids or retinoids all improve penetration — but none fully solve it. When evaluating topical peptide evidence, always ask: Was penetration confirmed, or was in vitro activity at concentrations far exceeding tissue-achievable levels used as a proxy?

Peptides with alternative systemic effects

Peptides with alternative systemic effects are a category whose primary mechanisms of action are not collagen synthesis or neuromuscular modulation. Rather, the systemic effects of these peptides have meaningful dermatologic implications or are being studied for direct cutaneous effects.

GLP-1 receptor agonists

Glucagon-like peptide-1 is an incretin hormone — itself a 30-amino-acid peptide — that regulates insulin secretion, gastric emptying and appetite. Pharmaceutical GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy, Novo Nordisk) and tirzepatide (Mounjaro/Zepbound, Eli Lilly) were developed for people with type 2 diabetes and obesity, but their dermatologic relevance is now impossible to ignore.

Positive dermatologic effects associated with GLP-1 use include an improvement in acanthosis nigricans secondary to insulin resistance reduction and a reduction in hidradenitis suppurativa disease activity via weight and metabolic improvement. Studies also suggest improvement in psoriasis, possibly through inflammatory pathway modulation independent of weight loss, as GLP-1 receptors are expressed on keratinocytes and immune cells. There are also early signals for rosacea and sebaceous activity reduction via sebocyte GLP-1 receptor expression.

There are also negative dermatologic effects. Some using GLP-1s develop “Ozempic face,” or accelerated facial volume loss from rapid weight reduction. Subcutaneous fat loss is not selective, and the resulting skin laxity can visibly age patients. Telogen effluvium, secondary to caloric restriction and rapid weight change, is frequently reported and generally transient.

There is no established evidence base for topical GLP-1 receptor agonist application. GLP-1 is a 30-amino-acid peptide (approximately 3,300 Da) and is far too large for meaningful stratum corneum penetration by conventional formulation. Some cosmetic companies have begun marketing “GLP-1 mimicking” peptides for topical use; these are largely without peer-reviewed clinical evidence and should be approached with appropriate skepticism.

BPC-157 (Body Protection Compound)

BPC-157 is a 15-amino-acid stable gastric pentadecapeptide derived from a region of human gastric juice protein. BPC-157 has attracted significant interest in sports medicine and biohacking communities for its purported wound-healing, tendon-repair and anti-inflammatory properties. Patients are increasingly asking about subcutaneous or oral administration.

Animal studies demonstrate accelerated wound healing with BPC-157, improved angiogenesis and collagen organization in skin wounds. A small number of human case reports exist. It is not FDA-approved for any indication. Evidence is entirely preclinical or anecdotal at the human level. Theoretical concerns include effects on tumor vascularity (angiogenic activity) in patients with occult malignancy.

Thymosin beta-4 (TB-500)

Thymosin beta-4 is a 43-amino-acid peptide involved in actin sequestration, cell migration and angiogenesis. Wound-healing data in animal models are compelling; human trials in wound healing exist but are limited. Like BPC-157, it is often used in biohacking communities as a subcutaneous injectable. Its wound-healing mechanism is plausible and partially supported preclinically, but clinical evidence in humans for cutaneous applications is insufficient for recommendation.

Longevity-associated peptides

Longevity-associated peptides are perhaps the most intellectually interesting, yet clinically premature, category. These are peptides associated with longevity pathways whose mechanisms are not primarily about restoring skin quality, but whose downstream effects on cellular aging, mitochondrial function or immune modulation make them relevant to the broader anti-aging conversation.

Epithalon (epitalon)

Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal peptide Epithalamin. It has been studied extensively in Russia since the 1970s by the late gerontologist and professor Vladimir Khavinson, MD, PhD. Epithalon is proposed to activate telomerase, elongating telomeres and thereby extending cellular lifespan. It has also been studied for effects on circadian rhythm regulation, cortisol normalization and immune modulation.

Epithalon’s longevity mechanism is said to be through telomere lengthening and epigenetic clock modulation, not direct collagen synthesis or neuromodulation. Animal studies in mice and rats show extended lifespan and reduced tumor incidence. Human studies, conducted primarily in the Russian gerontology literature, report improved sleep quality, melatonin normalization and reduced biological age markers.

The Russian literature, although substantial in volume, has not been widely replicated in Western peer-reviewed trials. Telomere elongation via a subcutaneously administered peptide is a compelling hypothesis; it is not yet established science in humans. Topical formulations exist but lack any plausible penetration mechanism to the nucleus.

From a safety standpoint, activating telomerase systemically carries a theoretical oncologic risk, as telomerase reactivation is a hallmark of malignant transformation. The long-term implications of sustained telomerase stimulation in humans without concurrent tumor surveillance are unknown.

Longevity mechanisms of GHK-Cu

Returning to GHK-Cu from the systemic longevity angle: Beyond its fibroblast-stimulating and wound-healing properties, GHK-Cu has been identified as a potent activator of multiple longevity-associated pathways. It resets gene expression in aged human fibroblasts toward a more youthful pattern, activates BDNF and nerve growth factor, and upregulates anti-inflammatory and antioxidant genes. A bioinformatic analysis of the GHK-Cu gene activation signature found overlaps with gene expression patterns associated with extended lifespan in model organisms.

This longevity mechanism of gene expression reprogramming is categorically different from its topical skin-tightening mechanism. This raises the question of whether systemic administration via subcutaneous injections, as practiced by some longevity medicine physicians, offers benefits beyond what topical application can achieve. Human systemic trial data remain limited. Critically, the systemic safety concerns flagged earlier apply with full force here. Copper homeostasis is tightly regulated and exogenous systemic delivery risks hepatotoxicity, pro-oxidant Fenton-type radical generation, and potentially contributions to neurodegeneration. The longevity hypothesis is intellectually compelling; it does not override the absence of a safe, established systemic dosing range in humans.

MOTS-c

MOTS-c is a mitochondrial-derived peptide encoded in the 12S rRNA of mitochondrial DNA. It regulates metabolic homeostasis, activates AMPK and improves insulin sensitivity. In animal models, administration of MOTS-c extends lifespan and counteracts age-related metabolic decline. Blood levels decline with age and are higher in centenarians than in controls in some studies, making it a compelling longevity biomarker candidate. Direct skin effects are not established. This is a research peptide; human clinical trials are in early stages. No human safety data exist for exogenous systemic MOTS-c administration outside of early-phase trials; effects on insulin signaling, cardiac function and immune modulation at supraphysiologic doses are unstudied.

Humanin

Humanin is another mitochondrial-derived peptide that was originally identified as neuroprotective. It inhibits apoptosis, activates STAT3 and counteracts amyloid-beta toxicity. Serum levels decline with age; offspring of centenarians have higher levels than controls. In mouse models, systemic humanin extends lifespan and protects against cardiovascular and metabolic disease. Some in vitro work suggests protection of dermal fibroblasts against UV-induced apoptosis. No topical or systemic clinical trials in humans for skin-specific endpoints exist. STAT3 activation, while anti-apoptotic in the aging context, is also a pathway implicated in oncogenesis; sustained systemic STAT3 stimulation without long-term safety monitoring raises legitimate concern.

Systemic safety: The underexamined question

Before summarizing the evidence, it is worth pausing on a category that receives almost no attention in the cosmeceutical and biohacking literature: the systemic safety profile of peptides with only topical evidence.

Patients are increasingly using these molecules via non-topical routes, whether through subcutaneous injection, oral supplementation or IV infusion, based on longevity protocols obtained through compounding pharmacies, online prescribers or unregulated suppliers. As dermatologists, we are positioned to be among the most informed clinicians on these molecules. That expertise carries a responsibility to address safety directly.

Systemic safety of copper peptide (GHK-Cu)

Copper is an essential trace element, but its homeostasis is exquisitely regulated by ceruloplasmin, metallothioneins and hepatic excretion. Exogenous systemic copper delivery bypasses these regulatory checkpoints. Known risks of copper excess include hepatotoxicity (copper accumulates in hepatocytes before systemic toxicity manifests), pro-oxidant catalysis via Fenton-type reactions generating hydroxyl radicals that damage lipids, proteins, and DNA, and emerging associations with neurodegeneration. Elevated copper has been implicated in Alzheimer’s disease pathophysiology. There is no established therapeutic index for GHK-Cu administered systemically in healthy adults for cosmetic purposes. Patients with Wilson’s disease or undiagnosed hepatic copper metabolism disorders face particular risk. Until pharmacokinetic and safety data from prospective human trials exist, systemic GHK-Cu cannot be endorsed.

Systemic safety of neuromodulatory peptides

The safety concern with systemic neuromodulatory peptides is both mechanistic and contextual. Topically, their effect is diffuse and surface-limited — a modest attenuation of superficial muscle contraction. Systemically, the same mechanisms become unpredictable. Argireline’s SNARE interference at systemic concentrations could theoretically affect autonomic neurotransmission (cardiac, gastrointestinal, glandular). Leuphasyl’s enkephalin pathway modulation could interact with endogenous opioid signaling. SYN-AKE’s nicotinic acetylcholine receptor antagonism, derived from viper venom pharmacology, raises the specter of dose-dependent neuromuscular blockade analogous to curare-type compounds.

None of these systemic risks have been studied in humans at pharmacologically relevant doses for injectable or oral administration. The absence of evidence is not evidence of absence. Instead, it reflects the fact that these molecules were developed for topical cosmetic use and never subjected to the systemic toxicology evaluation required for pharmaceutical approval. Patients acquiring these peptides as injectables from compounding pharmacies are, in effect, participating in uncontrolled safety experiments.

A note on compounding and regulatory status

None of the collagen-building or neuromodulatory topical cosmeceutical peptides are FDA-approved for systemic administration. When patients present with these molecules obtained via compounding pharmacies or online prescribers for injection or oral use, they are outside any regulated evidence framework.

The appropriate clinical response is not dismissal, but informed counseling. Discuss what the topical evidence supports, what systemic safety data do and do not exist, and what monitoring, such as hepatic function for copper peptides or neuromuscular assessment for neuromodulatory peptides, might be considered in patients who choose to continue use.

Clinical takeaways for dermatologists

For patients seeking topical anti-aging support, palmitoyl pentapeptide-4 (Matrixyl) and GHK-Cu have the strongest evidence and are appropriate first recommendations. Concentration and formulation matter — advise accordingly.

For patients asking about Botox alternatives in a serum, manage expectations explicitly. Argireline has real, if modest, data. SYN-AKE and Leuphasyl are reasonable additions in combination products but are not neurotoxin substitutes by any clinical measure.

For patients taking semaglutide or tirzepatide, anticipate volume loss conversations. Proactive discussion about fillers, biostimulators and skin-tightening modalities before significant weight loss is appropriate counseling, not upselling.

For patients asking about peptide longevity protocols, acknowledge the intellectual legitimacy of the question while being honest about the evidence gap. GHK-Cu has the most cross-category support. Epithalon, MOTS-c and humanin are biologically compelling but remain research-grade in humans.

For patients bringing in subcutaneous peptide stacks from compounding pharmacies, take a careful history. BPC-157 and TB-500 are unregulated research chemicals. GHK-Cu carries real systemic copper toxicity risk without an established safe dosing range. Neuromodulatory peptides administered systemically have unknown autonomic and neuromuscular safety profiles. The longevity peptides lack long-term human safety data. Your role is nonjudgmental harm reduction, informed counseling and — where patients continue use — appropriate monitoring.

The rapid expansion of the peptide market into injectable and oral formats has outpaced any safety evidence. As the physicians most familiar with cosmeceutical peptides, dermatologists are uniquely positioned to counsel patients accurately. The absence of published adverse event data does not mean these compounds are safe systemically. It means they have not been studied. That distinction matters enormously in informed consent.

The honest bottom line

Peptides are not monoliths. Some have legitimate, replicated clinical evidence for topical use. Some have compelling systemic evidence for specific indications. GLP-1s, for example, have transformed metabolic medicine. Some are at the frontier of longevity science with extraordinary preclinical promise and insufficient human data. And some — particularly copper peptides and neuromodulatory peptides, when taken systemically — carry safety risks that are neither well-characterized nor widely communicated to patients.

The clinician’s job is to hold all these truths simultaneously. Affirm the science where it exists, be honest about the gaps and name the risks that the wellness industry has little incentive to disclose.

For more information:

Macrene Alexiades, MD, PhD, is associate clinical professor at Yale University School of Medicine and director and founder of the Dermatology & Laser Surgery Center of New York. Alexiades is also a member of the Healio Dermatology Peer Perspective Board. Alexiades can be reached on Instagram @drmacrene.